Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic painA241045 and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population.A241165
NGF was first discovered in the 1950sA241180 and was the first neurotrophic factor to be identified and biochemically characterized.A241190 It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Fasinumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Fasinumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Fasinumab. |
| Estrone | Estrone may increase the thrombogenic activities of Fasinumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Fasinumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Fasinumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Fasinumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Fasinumab. |
| Estriol | Estriol may increase the thrombogenic activities of Fasinumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Fasinumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Fasinumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Fasinumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Fasinumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Fasinumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Fasinumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Fasinumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Fasinumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Fasinumab. |
| Equol | Equol may increase the thrombogenic activities of Fasinumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Fasinumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Fasinumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Fasinumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Fasinumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Fasinumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Fasinumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Fasinumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Fasinumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Fasinumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Fasinumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Fasinumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Fasinumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fasinumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Fasinumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Fasinumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Fasinumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fasinumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fasinumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Fasinumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fasinumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fasinumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fasinumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fasinumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fasinumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fasinumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fasinumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fasinumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fasinumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fasinumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fasinumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Fasinumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Fasinumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fasinumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fasinumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fasinumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Fasinumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Fasinumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Fasinumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Fasinumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Fasinumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Fasinumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Fasinumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Fasinumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Fasinumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Fasinumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Fasinumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Fasinumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Fasinumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Fasinumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Fasinumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Fasinumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Fasinumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Fasinumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Fasinumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Fasinumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Fasinumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Fasinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Fasinumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Fasinumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Fasinumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Fasinumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Fasinumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Fasinumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Fasinumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Fasinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Fasinumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Fasinumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Fasinumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fasinumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Fasinumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Fasinumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Fasinumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Fasinumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Fasinumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Fasinumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Fasinumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Fasinumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Fasinumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Fasinumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Fasinumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Fasinumab. |